1. World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD).WHO website. Updated November 2024. Accessed September 09, 2024. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD, 2024 report. GOLD website. Published December 2023. Accessed September 09, 2024. https://goldcopd.org/2024-gold-report/
3. Boers E, Barrett M, Su JG, et al. Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open. 2023;6(12):e2346598. https://doi.org/10.1001/jamanetworkopen.2023.46598
4. Liu Y, Carlson SA, Watson KB, Xu F, Greenlund KJ. Trends in the prevalence of chronic obstructive pulmonary disease among adults aged ≥18 Years - United States, 2011-2021. MMWR Morb Mortal Wkly Rep. 2023;72(46):1250-1256. https://doi.org/10.15585/mmwr.mm7246a1
5. Chen S, Kuhn M, Prettner K, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study. Lancet Glob Health. 2023;11(8):e1183-e1193. https://doi.org/10.1016/S2214-109X(23)00217-6
6. Lin CH, Cheng SL, Chen CZ, Chen CH, Lin SH, Wang HC. Current progress of COPD early detection: key points and novel strategies. Int J Chron Obstruct Pulmon Dis. 2023;18:1511-1524. https://doi.org/10.2147/COPD.S413969
7. Murgia N, Gambelunghe A. Occupational COPD-the most under-recognized occupational lung disease? Respirology. 2022;27(6):399-410. https://doi.org/10.1111/resp.14272
8. Scichilone N, Whittamore A, White C, Nudo E, Savella M, Lombardini M. The patient journey in chronic obstructive pulmonary disease (COPD): a human factors qualitative international study to understand the needs of people living with COPD. BMC Pulm Med. 2023;23(1):506. https://doi.org/10.1186/s12890-023-02796-8
9. Johansson H, Bertero C, Berg K, Jonasson LL. To live a life with COPD - the consequences of symptom burden. Int J Chron Obstruct Pulmon Dis. 2019;14:905-909. https://doi.org/10.2147/COPD.S192280
10. Anzueto A, Rogers S, Donato B, et al. Treatment patterns in patients with newly diagnosed COPD in the USA. BMC Pulm Med. 2024;24(1):395. https://doi.org/10.1186/s12890-024-03194-4
11. Siu DCH, Gafni-Lachter L. Addressing barriers to chronic obstructive pulmonary disease (COPD) care: three innovative evidence-based approaches: a review. Int J Chron Obstruct Pulmon Dis. 2024;19:331-341. https://doi.org/10.2147/COPD.S426050
12. Joo MJ, Lee TA, Weiss KB. Geographic variation of spirometry use in newly diagnosed COPD. Chest. 2008;134(1):38-45. https://doi.org/10.1378/chest.08-0013
13. Han MK, Kim MG, Mardon R, et al. Spirometry utilization for COPD: how do we measure up? Chest. 2007;132(2):403-409. https://doi.org/10.1378/chest.06-2846
14. Lamprecht B, Mahringer A, Soriano JB, Kaiser B, Buist AS, Studnicka M. Is spirometry properly used to diagnose COPD? Results from the BOLD study in Salzburg, Austria: a population-based analytical study. Prim Care Respir J. 2013;22(2):195-200. https://doi.org/10.4104/pcrj.2013.00032
15. Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(9):1130-1139. https://doi.org/10.1164/rccm.201804-0621CI
16. Aggarwal AN, Gupta D, Agarwal R, Jindal SK. Comparison of the lower confidence limit to the fixed-percentage method for assessing airway obstruction in routine clinical practice. Respir Care. 2011;56(11):1778-1784. https://doi.org/10.4187/respcare.01160
17. Chaiwong W, Uthaikhup S, Liwsrisakun C, Pothirat C. Effect of changing reference equations for spirometry interpretation in Thai people. J Thorac Dis. 2019;11(1):113-122. https://doi.org/10.21037/jtd.2018.11.06
18. Hangaard S, Helle T, Nielsen C, Hejlesen OK. Causes of misdiagnosis of chronic obstructive pulmonary disease: a systematic scoping review. Respir Med. 2017;129:63-84. https://doi.org/10.1016/j.rmed.2017.05.015
19. Brems JH, Balasubramanian A, Raju S, et al. Changes in spirometry interpretative strategies: implications for classifying COPD and predicting exacerbations. Chest. 2024;166(2):294-303. https://doi.org/10.1016/j.chest.2024.03.034
20. Schiavi E, Ryu MH, Martini L, et al. Application of the European Respiratory Society/American Thoracic Society spirometry standards and race-neutral equations in the COPDGene study. Am J Respir Crit Care Med. 2024;210(11):1317-1328. https://doi.org/10.1164/rccm.202311-2145OC
21. Athlin Å, Lisspers K, Hasselgren M, et al. Diagnostic spirometry in COPD is increasing, a comparison of two Swedish cohorts. NPJ Prim Care Respir Med. 2023;33(1):23. https://doi.org/10.1038/s41533-023-00345-8
22. Jones RC, Price D, Ryan D, et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 2014;2(4):267-276. https://doi.org/10.1016/S2213-2600(14)70008-6
23. Perez X, Wisnivesky JP, Lurslurchachai L, Kleinman LC, Kronish IM. Barriers to adherence to COPD guidelines among primary care providers. Respir Med. 2012;106(3):374-381. https://doi.org/10.1016/j.rmed.2011.09.010
24. Akhtar R, Wilson A. A comparison of spirometry in general practice and a pulmonary function laboratory. Prim Care Respir J. 2005;14(4):215-220. https://doi.org/10.1016/j.pcrj.2004.12.005
25. Starren ES, Roberts NJ, Tahir M, et al. A centralised respiratory diagnostic service for primary care: a 4-year audit. Prim Care Respir J. 2012;21(2):180-186. https://doi.org/10.4104/pcrj.2012.00013
26. Perret J, Yip SWS, Idrose NS, et al. Undiagnosed and 'overdiagnosed' COPD using postbronchodilator spirometry in primary healthcare settings: a systematic review and meta-analysis. BMJ Open Respir Res. 2023;10(1):e001478. https://doi.org/10.1136/bmjresp-2022-001478
27. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 2001;119(6):1691-1695. https://doi.org/10.1378/chest.119.6.1691
28. Fromer L. Diagnosing and treating COPD: understanding the challenges and finding solutions. Int J Gen Med. 2011;4:729-739. https://doi.org/10.2147/IJGM.S21387
29. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95-99. https://doi.org/10.2147/COPD.S27480
30. Bhatt SP, Nakhmani A, Fortis S, et al. STAR has better discrimination for mortality than ERS/ATS chronic obstructive pulmonary disease severity classification. Am J Respir Crit Care Med. 2024;210(11):1376-1379. https://doi.org/10.1164/rccm.202311-2172LE
31. Miravitlles M, Anzueto A. Chronic respiratory infection in patients with chronic obstructive pulmonary disease: what is the role of antibiotics? Int J Mol Sci. 2017;18(7):1344. https://doi.org/10.3390/ijms18071344
32. Zysman M, Raherison-Semjen C. Women's COPD. Front Med (Lausanne). 2021;8:600107. https://doi.org/10.3389/fmed.2021.600107
33. Somayaji R, Chalmers JD. Just breathe: a review of sex and gender in chronic lung disease. Eur Respir Rev. 2022;31(163):210111. https://doi.org/10.1183/16000617.0111-2021
34. Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. https://doi.org/10.1186/s12931-017-0548-3
35. Berger BE, Kapella MC, Larson JL. The experience of stigma in chronic obstructive pulmonary disease. West J Nurs Res. 2011;33(7):916-932. https://doi.org/10.1177/0193945910384602
36. Mathioudakis AG, Ananth S, Vestbo J. Stigma: an unmet public health priority in COPD. Lancet Respir Med. 2021;9(9):955-956. https://doi.org/10.1016/S2213-2600(21)00316-7
37. Madawala S, Osadnik CR, Warren N, Kasiviswanathan K, Barton C. Healthcare experiences of adults with COPD across community care settings: a meta-ethnography. ERJ Open Res. 2023;9(1):00581-02022. https://doi.org/10.1183/23120541.00581-2022
38. Boland VC, Mattick RP, McRobbie H, Siahpush M, Courtney RJ. "I'm not strong enough; I'm not good enough. I can't do this, I'm failing"- A qualitative study of low-socioeconomic status smokers' experiences with accessing cessation support and the role for alternative technology-based support. Int J Equity Health. 2017;16(1):196. https://doi.org/10.1186/s12939-017-0689-5
39. Chang YY, Dai YT, Chien NH, Chan HY. The lived experiences of people with chronic obstructive pulmonary disease: a phenomenological study. J Nurs Scholarsh. 2016;48(5):466-471. https://doi.org/10.1111/jnu.12230
40. Philip K, Gaduzo S, Rogers J, Laffan M, Hopkinson NS. Patient experience of COPD care: outcomes from the British Lung Foundation Patient Passport. BMJ Open Respir Res. 2019;6(1):e000478. https://doi.org/10.1136/bmjresp-2019-000478
41. Higginson R, Parry A. Managing chronic obstructive pulmonary disease in the community setting. Br J Community Nurs. 2018;23(1):6-12. https://doi.org/10.12968/bjcn.2018.23.1.6
42. Madawala S, Enticott J, Sturgiss E, Selamoglu M, Barton C. The impact of smoking status on anticipated stigma and experience of care among smokers and ex-smokers with chronic illness in general practice. Chronic Illn. 2023;19(3):557-570. https://doi.org/10.1177/17423953221101337
43. Jacobs SS, Krishnan JA, Lederer DJ, et al. Home oxygen therapy for adults with chronic lung disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;202(10):e121-e141. https://doi.org/10.1164/rccm.202009-3608ST
44. Bueno GH, Campos CJG, Turato ER, et al. Experiences in elderly people with chronic obstructive pulmonary disease in relation to the use of long-term home oxygen therapy: a qualitative study about feelings attributed to therapy. BMC Pulm Med. 2022;22(1):96. https://doi.org/10.1186/s12890-022-01891-6
45. Arnold E, Bruton A, Donovan-Hall M, Fenwick A, Dibb B, Walker E. Ambulatory oxygen: why do COPD patients not use their portable systems as prescribed? A qualitative study. BMC Pulm Med. 2011;11:9. https://doi.org/10.1186/1471-2466-11-9
46. Zamzam MA, Azab NY, El Wahsh RA, Ragab AZ, Allam EM. Quality of life in COPD patients. Egypt J Chest Dis Tuberc. 2012;61(4):281-289. https://doi.org/10.1016/j.ejcdt.2012.08.012
47. Garudadri S, Woodruff PG. Targeting chronic obstructive pulmonary disease phenotypes, endotypes, and biomarkers. Ann Am Thorac Soc. 2018;15(Suppl 4):S234-S238. https://doi.org/10.1513/AnnalsATS.201808-533MG
48. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410-419. https://doi.org/10.1183/13993003.01359-2015
49. Franssen FM, Alter P, Bar N, et al. Personalized medicine for patients with COPD: where are we? Int J Chron Obstruct Pulmon Dis. 2019;14:1465-1484. https://doi.org/10.2147/COPD.S175706
50. Tashkin DP. Smoking cessation in COPD: confronting the challenge. Intern Emerg Med. 2021;16(3):545-547. https://doi.org/10.1007/s11739-021-02710-2
51. Ji Z, Jareño-Esteban JJ, de Miguel-Díez J. Role of vaccines in COPD patients. Open Respir Arch. 2022;4(3):100191. https://doi.org/10.1016/j.opresp.2022.100191
52. Simon S, Joean O, Welte T, Rademacher J. The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus. Eur Respir Rev. 2023;32(169):230034. https://doi.org/10.1183/16000617.0034-2023
53. American Lung Association (ALA). Understanding your COPD medications. ALA website. Updated April 2025. Accessed October 28, 2024. https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treating/copd-medications#:~:text=Short%2Dacting%20beta%2Dagonists%20(,to%20be%20taken%20every%20day)
54. Ridolo E, Montagni M, Olivieri E, Riario-Sforza GG, Incorvaia C. Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:425-432. https://doi.org/10.2147/COPD.S49179
55. Mammen MJ, Pai V, Aaron SD, Nici L, Alhazzani W, Alexander PE. Dual LABA/LAMA therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. A systematic review and meta-analysis in support of the American Thoracic Society clinical practice guideline. Ann Am Thorac Soc. 2020;17(9):1133-1143. https://doi.org/10.1513/AnnalsATS.201912-915OC
56. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029-1036. https://doi.org/10.1136/thoraxjnl-2012-202872
57. Bhatt SP, Blauer-Peterson C, Buysman EK, Bengtson LGS, Palli SR. Trends and characteristics of global initiative for chronic obstructive lung disease guidelines-discordant prescribing of triple therapy among patients with COPD. Chronic Obstr Pulm Dis. 2022;9(2):135-153. https://doi.org/10.15326/jcopdf.2021.0256
58. Brunton SA, Hogarth DK. Overuse of long-acting beta(2)-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns. Postgrad Med. 2023;135(8):784-802. https://doi.org/10.1080/00325481.2023.2284650
59. Levy ML, Carroll W, Izquierdo Alonso JL, Keller C, Lavorini F, Lehtimäki L. Understanding dry powder inhalers: key technical and patient preference attributes. Adv Ther. 2019;36(10):2547-2557. https://doi.org/10.1007/s12325-019-01066-6
60. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:381-390. https://doi.org/10.2147/COPD.S3391
61. Dekhuijzen PN, Lavorini F, Usmani OS. Patients' perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®). Patient Prefer Adherence. 2016;10:1561-1572. https://doi.org/10.2147/PPA.S82857
62. Barjaktarevic IZ, Milstone AP. Nebulized therapies in COPD: past, present, and the future. Int J Chron Obstruct Pulmon Dis. 2020;15:1665-1677. https://doi.org/10.2147/COPD.S252435
63. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):10. https://doi.org/10.1186/s12931-017-0710-y
64. Ocakli B, Ozmen I, Tunçay EA, et al. A comparative analysis of errors in inhaler technique among COPD versus asthma patients. Int J Chron Obstruct Pulmon Dis. 2018;13:2941-2947. https://doi.org/10.2147/COPD.S178951
65. Baker DW, DeWalt DA, Schillinger D, et al. Teach to goal: theory and design principles of an intervention to improve heart failure self-management skills of patients with low health literacy. J Health Commun. 2011;16(Suppl 3):73-88. https://doi.org/10.1080/10810730.2011.604379
66. Press VG, Arora VM, Trela KC, et al. Effectiveness of interventions to teach metered-dose and diskus inhaler techniques. A randomized trial. Ann Am Thorac Soc. 2016;13(6):816-824. https://doi.org/10.1513/AnnalsATS.201509-603OC
67. Marko M, Pawliczak R. Inhalation technique-related errors after education among asthma and COPD patients using different types of inhalers - systematic review and meta-analysis. NPJ Prim Care Respir Med. 2025;35(1):15. https://doi.org/10.1038/s41533-025-00422-0
68. Klijn SL, Hiligsmann M, Evers SMAA, Román-Rodríguez M, van der Molen T, van Boven JFM. Effectiveness and success factors of educational inhaler technique interventions in asthma and COPD patients: a systematic review. NPJ Prim Care Respir Med. 2017;27(1):24. https://doi.org/10.1038/s41533-017-0022-1
69. Axtell S, Haines S, Fairclough J. Effectiveness of various methods of teaching proper inhaler technique. J Pharm Pract. 2017;30(2):195-201. https://doi.org/10.1177/0897190016628961
70. Mayzel B, Muench S, Lauster C. Impact of pharmacist education on inhaler technique and adherence in an outpatient clinic. Hosp Pharm. 2022;57(3):402-407. https://doi.org/10.1177/00185787211046863
71. Paoletti G, Keber E, Heffler E, et al. Effect of an educational intervention delivered by pharmacists on adherence to treatment, disease control and lung function in patients with asthma. Respir Med. 2020;174:106199. https://doi.org/10.1016/j.rmed.2020.106199
72. Vincken W, Levy ML, Scullion J, Usmani OS, Dekhuijzen PNR, Corrigan CJ. Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res. 2018;4(2):00065-02018. https://doi.org/10.1183/23120541.00065-2018
73. Larsen DL, Gandhi H, Pollack M, Feigler N, Patel S, Wise RA. The quality of care and economic burden of COPD in the United States: considerations for managing patients and improving outcomes. Am Health Drug Benefits. 2022;15(2):57-64.
74. Stolbrink M, Thomson H, Hadfield RM, et al. The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review. Lancet Glob Health. 2022;10(10):e1423-e1442. https://doi.org/10.1016/S2214-109X(22)00330-8
75. Chetty U, McLean G, Morrison D, Agur K, Guthrie B, Mercer SW. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):e321-e328. https://doi.org/10.3399/bjgp17X690605
76. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med. 2012;12:26. https://doi.org/10.1186/1471-2466-12-26
77. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-161. https://doi.org/10.1164/rccm.201201-0034OC
78. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36(4):575-591. https://doi.org/10.1055/s-0035-1556063
79. Reis LF, Guimarães FS, Fernandes SJ, et al. A long-term pulmonary rehabilitation program progressively improves exercise tolerance, quality of life and cardiovascular risk factors in patients with COPD. Eur J Phys Rehabil Med. 2013;49(4):491-497.
80. Coventry PA, Hind D. Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: systematic review and meta-analysis. J Psychosom Res. 2007;63(5):551-565. https://doi.org/10.1016/j.jpsychores.2007.08.002
81. McDonald VM, Gibson PG, Scott HA, et al. Should we treat obesity in COPD? The effects of diet and resistance exercise training. Respirology. 2016;21(5):875-882. https://doi.org/10.1111/resp.12746
82. Wouters EF, Posthuma R, Koopman M, et al. An update on pulmonary rehabilitation techniques for patients with chronic obstructive pulmonary disease. Expert Rev Respir Med. 2020;14(2):149-161. https://doi.org/10.1080/17476348.2020.1700796
83. Myers LC, Quint JK, Hawkins NM, et al. A research agenda to improve outcomes in patients with chronic obstructive pulmonary disease and cardiovascular disease: an official American Thoracic Society Research statement. Am J Respir Crit Care Med. 2024;210(6):715-729. https://doi.org/10.1164/rccm.202407-1320ST
84. Toubes-Navarro ME, Gude-Sampedro F, Álvarez-Dobaño JM, et al. A pulmonary rehabilitation program reduces hospitalizations in chronic obstructive pulmonary disease patients: a cost-effectiveness study. Ann Thorac Med. 2023;18(4):190-198. https://doi.org/10.4103/atm.atm_70_23
85. Mosher CL, Nanna MG, Jawitz OK, et al. Cost-effectiveness of pulmonary rehabilitation among US adults with chronic obstructive pulmonary disease. JAMA Netw Open. 2022;5(6):e2218189. https://doi.org/10.1001/jamanetworkopen.2022.18189
86. Blackstock FC, Lareau SC, Nici L, et al. Chronic obstructive pulmonary disease education in pulmonary rehabilitation. An official American Thoracic Society/Thoracic Society of Australia and New Zealand/Canadian Thoracic Society/British Thoracic Society workshop report. Ann Am Thorac Soc. 2018;15(7):769-784. https://doi.org/10.1513/AnnalsATS.201804-253WS
87. Roberts NJ, Kidd L, Kirkwood K, Cross J, Partridge MR. A systematic review of the content and delivery of education in pulmonary rehabilitation programmes. Respir Med. 2018;145:161-181. https://doi.org/10.1016/j.rmed.2018.11.002
88. Mendes MA, Rodrigues G, Janssen DJA, Spruit MA, Marques A. Understanding the determinants and outcomes of education in pulmonary rehabilitation moving toward person-centered care. Chest. 2025; 167(6):1615-1627. https://doi.org/10.1016/j.chest.2025.01.005
89. Effing TW, Vercoulen JH, Bourbeau J, et al. Definition of a COPD self-management intervention: international expert group consensus. Eur Respir J. 2016;48(1):46-54. https://doi.org/10.1183/13993003.00025-2016
90. Esteban C, Arostegui I, Aramburu A, et al. Changes in health-related quality of life as a marker in the prognosis in COPD patients. ERJ Open Res. 2022;8(1):00181-02021. https://doi.org/10.1183/23120541.00181-2021
91. Baiardini I, Contoli M, Corsico AG, et al. Exploring the relationship between disease awareness and outcomes in patients with chronic obstructive pulmonary disease. Respiration. 2021;100(4):291-297. https://doi.org/10.1159/000513953
92. National Institute for Health and Care Excellence (NICE). Overview: chronic obstructive pulmonary disease in over 16s: diagnosis and management guidance. NICE website. Published December 2018. Updated July 2019. Accessed October 28, 2024. https://www.nice.org.uk/guidance/ng115
93. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med. 2003;163(5):585-591. https://doi.org/10.1001/archinte.163.5.585
94. Jordan RE, Majothi S, Heneghan NR, et al. Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. Health Technol Assess. 2015;19(36):1-516. https://doi.org/10.3310/hta19360
95. Murphy LA, Harrington P, Taylor SJ, et al. Clinical-effectiveness of self-management interventions in chronic obstructive pulmonary disease: An overview of reviews. Chron Respir Dis. 2017;14(3):276-288. https://doi.org/10.1177/1479972316687208
96. Aravantinou-Karlatou A, Bouloukaki I, Christodoulakis A, Tsiligianni I. The influence of social support in PROMs of patients with COPD in primary care: a scoping review. Healthcare (Basel). 2023;11(24):3141. https://doi.org/10.3390/healthcare11243141
97. Jonkman NH, Westland H, Trappenburg JC, et al. Characteristics of effective self-management interventions in patients with COPD: individual patient data meta-analysis. Eur Respir J. 2016;48(1):55-68. https://doi.org/10.1183/13993003.01860-2015
98. Pinnock H, Steed L, Jordan R. Supported self-management for COPD: making progress, but there are still challenges. Eur Respir J. 2016;48(1):6-9. https://doi.org/10.1183/13993003.00576-2016
99. Qiu S, Zhong X. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2017;11(3):147-155. https://doi.org/10.1177/1753465816682677
100. Naderi N, Assayag D, Mostafavi-Pour-Manshadi SM, et al. Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. Respir Med. 2018;138:129-136. https://doi.org/10.1016/j.rmed.2018.03.035
101. Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:81-90. https://doi.org/10.2147/COPD.S89849
102. Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023;208(4):406-416. https://doi.org/10.1164/rccm.202306-0944OC
103. Kersul AL, Cosio BG. Biologics in COPD. Open Respir Arch. 2024;6(2):100306. https://doi.org/10.1016/j.opresp.2024.100306
104. Mullard A. FDA approves first monoclonal antibody for COPD. Nat Rev Drug Discov. 2024;23(11):805. https://doi.org/10.1038/d41573-024-00164-7
105. Li H, Liu DH, Chen LL, et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother. 2014;58(1):511-517. https://doi.org/10.1128/AAC.02067-13
106. Joo H, Han D, Lee JH, Rhee CK. Incidence of adverse effects and discontinuation rate between patients receiving 250 micrograms and 500 micrograms of roflumilast: a comparative study. Tuberc Respir Dis (Seoul). 2018;81(4):299-304. https://doi.org/10.4046/trd.2018.0015
107. Shibuya M, Yamamoto S, Kobayashi S, et al. Pulmonary rehabilitation for patients after COPD exacerbation. Respir Care. 2022;67(3):360-369. https://doi.org/10.4187/respcare.09066
108. Meneses-Echavez JF, Chavez Guapo N, Loaiza-Betancur AF, Machado A, Bidonde J. Pulmonary rehabilitation for acute exacerbations of COPD: a systematic review. Respir Med. 2023;219:107425. https://doi.org/10.1016/j.rmed.2023.107425
109. Holland AE, Cox NS, Houchen-Wolloff L, et al. Defining modern pulmonary rehabilitation. An official American Thoracic Society workshop report. Ann Am Thorac Soc. 2021;18(5):e12-e29. https://doi.org/10.1513/AnnalsATS.202102-146ST